Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:SLNO 30 December 2025 - 7 April 2026

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics withdrew its European filing for VIOKAT on Tuesday, halting a regulatory review that was expected to conclude in 2026. The move came one day after Neurocrine Biosciences agreed to acquire Soleno for $2.9 billion in cash, or $53 a share. Vykat XR, Soleno’s only marketed product, generated $190.4 million in 2025 U.S. sales. Neurocrine said it has no immediate plans for a European launch.
7 April 2026
···
Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Neurocrine Biosciences will acquire Soleno Therapeutics for $53 a share in cash, valuing Soleno at $2.9 billion. The deal gives Neurocrine Vykat XR, the only FDA-approved treatment for hyperphagia in Prader-Willi syndrome. Soleno shares last traded at $52.25. The transaction is expected to close within 90 days, pending regulatory and shareholder approval.
7 April 2026
···
Soleno Therapeutics stock jumps nearly 9% today — what SLNO traders are watching next

Soleno Therapeutics stock jumps nearly 9% today — what SLNO traders are watching next

Soleno Therapeutics shares jumped 8.9% to $42.00 Monday, outpacing a broad biotech rally. The move follows attention on VYKAT XR’s U.S. launch, with preliminary 2025 revenue reported at up to $191 million and 1,250 patient starts. Investors are awaiting full financial results in late February and monitoring upcoming investor conference appearances. No new company news was released Monday.
2 February 2026
·
Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Soleno Therapeutics shares fell 5.6% to $42.95 Friday, underperforming the biotech sector after law firms announced “investigations” tied to past short-seller claims about Vykat XR. The company reported $66 million in quarterly revenue from the drug, approved for Prader-Willi syndrome, with 1,043 patient start forms since March. The stock hovered just above its 52-week low. Next update expected late February.
9 January 2026
··

Stock Market Today

  • Morningstar Recommends 3 ETFs to Hedge Against Market Volatility
    April 9, 2026, 11:17 AM EDT. Morningstar, a leading investment research firm, has identified three exchange-traded funds (ETFs) as effective tools to guard against fresh market volatility. These ETFs offer diversified exposure across various asset classes, aiming to reduce risk amid uncertain market conditions. As investors brace for potential fluctuation, Morningstar's picks provide a strategic approach to navigate volatility through low-cost, flexible investment vehicles. This guidance aligns with the growing demand for resilient portfolios adapting to unpredictable economic shifts. The recommended ETFs target sectors and themes that historically perform well during tumultuous periods, helping investors balance growth and protection.

Latest article

ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

9 April 2026
ServiceNow shares dropped 5.1% to $92.45 by 10:20 a.m. EDT Thursday, hitting a new 52-week low after analysts at Stifel, BTIG, and Goldman Sachs cut price targets citing weak federal spending and limited 2026 growth. The company announced it will integrate AI, data, security, and governance into all products ahead of first-quarter results due April 22.
SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

9 April 2026
SoFi Technologies shares fell 1.9% to $16.18 Thursday after KBW and Wells Fargo cut price targets ahead of first-quarter results due April 29. The moves follow Muddy Waters’ short position and claims of accounting issues, which SoFi denies. Affirm and LendingClub also traded lower. Barclays and other banks have trimmed targets as concerns mount over credit quality and sector valuations.
Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

9 April 2026
Tesla is developing a smaller, cheaper electric SUV to be built first in Shanghai, sources said. The new model would cost less than the Model 3 and be smaller than the Model Y. Tesla produced 408,386 vehicles but delivered only 358,023 in Q1, as U.S. demand weakened and competition increased. Shares fell 0.8% Thursday.
Grab Holdings Bets on AI as Group Ride Tool Targets 40% Lower Fares

Grab Holdings Bets on AI as Group Ride Tool Targets 40% Lower Fares

9 April 2026
Grab Holdings launched 13 new AI-powered products in Jakarta, including a “Group Ride” feature that can cut fares by up to 40% for shared routes. CEO Anthony Tan said the tools aim to offset rising fuel costs and support demand as households tighten spending. The company’s 2026 revenue and profit forecasts remain below analyst expectations. Grab’s $600 million deal to buy Foodpanda Taiwan is pending regulatory approval.
Nokia Oyj AI Data Center Push Gets Lift From Fifth Straight GigaOm Leader Ranking

Nokia Oyj AI Data Center Push Gets Lift From Fifth Straight GigaOm Leader Ranking

9 April 2026
Nokia was named a Leader and Outperformer in GigaOm’s 2026 Radar for data center switching for the fifth year in a row, competing with Cisco, Arista, and HPE Juniper. Shares fell 1.05% in Helsinki ahead of Thursday’s annual meeting, where board changes and a dividend of up to 14 euro cents per share will be considered.
Go toTop